https://www.selleckchem.com/pr....oducts/bay-2666605.h
The efficacy and safety of low-dose anti-PD1 antibodies in relapsed/refractory classical Hodgkin lymphoma (cHL) require confirmation. Pembrolizumab (100 mg every 3 weeks, Q3W) or nivolumab (40 mg Q2W) were administered to patients with relapsed/refractory cHL. In the pembrolizumab cohort (N = 11), who had failed a median of three (1-6) therapies (brentuximab vedotin [BV] 91%; autologous hematopoietic stem cell transplantation [auto-HSCT] 18%), the overall response rate (ORR) by positron emission tomography-computed tomography was 10
پسندیدن
اظهار نظر
اشتراک گذاری
